

### 4.9.3 – New policies in development, at validation, proposed and on hold (66)

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
SS	143	Complex Spinal Surgery	Service Specification	Neurosciences and Long-term Conditions	Prompted by the work being carried out by the collaborative on spinal surgery	New in progress
PPS	153	Complex Obesity Surgery (children) for severe and complex obesity	Policy Position Statement	Women and Children	Not funded following CIAG in 2017/8 but subsequently approved by JCC	New in progress
CP	165	Targeted therapies for the treatment of pulmonary hypertension in Adults	Commissioning Policy	Cardiac	Development of an NWJCC policy. To date we have been using the NHS England policy.	Proposed
CP	170	Cyropreservation of gametes	Commissioning Policy	Women and Children		On hold
SS	171	Paediatric Surgery	Service Specification	Women and Children	Identified as a gap in the NWJCC portfolio of service specifications	New in progress
SS	180	Prolonged Disorders of Consciousness	Service Specification	Neurosciences and Long-term Conditions	Development of a dedicated NWJCC policy	On hold
SS	190	Neonatal Transportation	Service Specification	Ambulance 111	Development of a dedicated NWJCC policy	New in progress
CP	192	Percutaneous Patent Foramen Closures (PPFOC)	Commissioning Policy	Cardiac	Development of a dedicated NWJCC policy	Proposed
SS	194	Cystic Fibrosis (Children)	Service Specification	Women and Children	Development of a NWJCC dedicated policy	New in progress
SS	200	Cardiac Transplantation	Service Specification	Cardiac		On hold
SS	202	High Consequence Infectious Diseases, Specialist Isolation	Service Specification	Cardiac		New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
CP	204	Inherited Metabolic Disease	Commissioning Policy	Neurosciences and Long-term Conditions		New in progress
SS	207	Inherited Cardiac Conditions	Service Specification	Cardiac		New in progress
CP	210	Severe Intestinal Failure	Commissioning Policy	Neurosciences and Long-term Conditions		New in progress
SS	210	Severe Intestinal Failure	Service Specification	Neurosciences and Long-term Conditions		New in progress
SS	216	Lymphoma Pathology	Service Specification	Cancer and Blood		On hold
PPS	225	Allogeneic HSCT for primary immunodeficiencies	Policy Position Statement	Cancer and Blood		On hold
SS	231	Specialised Paediatric ENT	Service Specification	Women and Children		On hold
PPS	242	Percutaneous patent foramen ovale closure for the prevention of recurrent cerebral embolic stroke in adults (around age 60 years and under)	Policy Position Statement	Cardiac		New in progress
SS	243	Pulmonary Hypertention Centre - Shared Care (Adults)	Service Specification	Cardiac		New in progress
SS	246	Specialist Mesothelioma Multi-Disciplinary Team	Service Specification	Cancer and Blood		On hold
PPS	255	Roxadustat for treating symptomatic anaemia in chronic kidney disease	Policy Position Statement	Welsh Kidney Network	NICE TA807 published 13 July 2022	Proposed

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
PPS	260	Drug treatment for atypical haemolytic uraemic syndrome (aHUS)	Policy Position Statement	Welsh Kidney Network	Developed to replace CP98 which was based on NICE HST1 and expanded to include NICE TA710 published on 23 June 2021	New in progress
CP	264	Nitisinone for the treatment of adults patients with alkaptonuria	Commissioning Policy	Neurosciences and Long-term Conditions	07/12/2022 - from prioritisation	On hold
CP	268	Paediatric Rehabilitation	Commissioning Policy	Women and Children	Created 10/01/2023 to replace CP160	On hold
SS	268	Paediatric Rehabilitation	Service Specification	Women and Children	Created 10/01/2023 to replace CP160	On hold
CP	269	Paediatric Oncology: Principal Treatment Centre	Commissioning Policy	Women and Children	Created 10/01/2023 to replace services for Children with Cancer	New in progress
SS	270	Skin Camouflage	Service Specification	Mental Health and Vulnerable Groups		New in progress
CP	275	Specialised paediatric respiratory	Commissioning Policy	Women and Children		On hold
SS	275	Specialised paediatric respiratory	Service Specification	Women and Children		On hold
CP	276	Paediatric Infectious Diseases	Commissioning Policy	Women and Children		New in progress
SS	276	Paediatric Infectious Diseases	Service Specification	Women and Children		New in progress
SS	287	Acute Leukaemia Immunophenotyping	Service Specification	Cancer and Blood		On hold
SS	288	All Wales Acute Leukaemia MDT	Service Specification	Cancer and Blood		On hold
CP	289	Gender Identity Services for Adults (Surgical Interventions)	Commissioning Policy	Mental Health and Vulnerable Groups		New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
PPS	292	Ruxolitinib for treating Acute Graft Versus Host Disease that responds inadequately to corticosteroids in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE TA1054 published 15 April 2025	At validation
PPS	294	ECMO for respiratory failure in adults	Policy Position Statement	Cancer and Blood		New in progress
PPS	303	Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	Policy Position Statement	Women and Children	NICE TA977 published 29 May 2024	New in progress
PPS	304	Etranacogene dezaparvec for treating moderately severe or severe haemophilia B (adults)	Policy Position Statement	Cancer and Blood	NICE TA989 published 24 July 2024	New in progress
PPS	305	Exagamglogene autotemcel for treating transfusion dependent beta-thalassaemia	Policy Position Statement	Cancer and Blood	NICE final draft guidance published 08/08/2024 NICE TA1003 published 11 September 2024	New in progress
SS	309	Tier 4 Forensic Child and Adolescent Mental Health Service, Forensic Adolescent Consultation Service - Youth Justice Services	Service Specification	Mental Health and Vulnerable Groups		On hold
SS	310	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis (SSAS)	Service Specification	Cardiac		New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
PPS	314	Rituximab for treatment of acute thrombotic thrombocytopenic purpura (TTP)	Policy Position Statement	Cancer and Blood	<a href="#">NHS England » Rituximab for the treatment in acute Thrombotic Thrombocytopenic Purpura (TTP) and elective therapy to prevent TTP relapse</a> At prioritisation in 2024	On hold
SS	316	Specialised Paediatric Ophthalmology	Service Specification	Women and Children		New in progress
SS	318	Clinical Neurophysiology (all ages)	Service Specification	Neurosciences and Long-term Conditions	NWJCC commissioning this service from 1 April 2025	New in progress
PPS	319	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE TA1044 published 26 February 2025	New in progress
PPS	320	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable	Policy Position Statement	Cancer and Blood	NICE TA1048 published 26 March 2025	New in progress
PPS	321	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	Policy Position Statement	Women and Children	NICE TA 1038 published 12 February 2025	New in progress
PPS	322	Vamorolone for treating Duchenne muscular dystrophy in people 4 -17 years of age	Policy Position Statement	Women and Children	NICE TA1031 published 16 January 2025	New in progress
PPS	323	Talimogene laherparepvec for treating unresectable metastatic melanoma	Policy Position Statement	Cancer and Blood	NICE TA410 published 28 September 2016	New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
SS	324	Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke	Service Specification	Neurosciences and Long-term Conditions	Service specification to sit alongside CP168 commissioning policy	New in progress
PPS	327	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over	Policy Position Statement	Cancer and Blood	NICE TA1051 published 2 April 2025	New in progress
PPS	328	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE HST 33 published 23 April 2025	New in progress
PPS	329	Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE TA1073 published 24 June 2025 <a href="https://www.nice.org.uk/guidance/ta1073/chapter/1-Recommendations">https://www.nice.org.uk/guidance/ta1073/chapter/1-Recommendations</a>	New in progress
SS	330	Electronic Assistive Technology (EAT)	Service Specification	Neurosciences and Long-term Conditions		New in progress
SS	331	Online Digital Mental Health Therapies	Service Specification	Mental Health and Vulnerable Groups		New in progress
SS	332	Functional Neurosurgical Service for patients with movement disorders (for people aged 16 and over)	Service Specification	Neurosciences and Long-term Conditions		New in progress
PPS	333	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	Policy Position Statement	Cancer and Blood	NICE TA872 published 28 Feb 2023	New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
PPS	334	Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Policy Position Statement	Cancer and Blood	NICE TA895 published 7 June 2023 - managed access agreement	New in progress
PPS	335	Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma	Policy Position Statement	Cancer and Blood	NICE TA677 published 24 February 2021 - managed access agreement	New in progress
PPS	336	Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	Policy Position Statement	Cancer and Blood	NICE TA893 published 7 June 2023 - managed access agreement	New in progress
PPS	337	Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	Policy Position Statement	Cancer and Blood	NICE TA975 published 15 May 2024	New in progress
PPS	338	Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia	Policy Position Statement	Cancer and Blood	NICE TA1116 published 11 December 2025	New in progress
PPS	339	Anakinra for treating Still's disease	Policy Position Statement	Women and Children	NICE TA685 published 31 March 2021	New in progress
PPS	340	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	Policy Position Statement	Women and Children	NICE TA1039 published 12 February	New in progress

Ref	No	Name of Policy	Policy Type	Commissioning Team	Development information/rationale	Policy Status
PPS	341	Growth Hormone for Paediatrics	Policy Position Statement	Women and Children	NICE TA 863 published 1 February 2023 NICE TA 1066 published 3 June 2025 NICE TA 188 published 26 May 2010	New in progress